Eris acquired Biocon Biologics' domestic branded formulation business for Rs 1,242 crore in Q4FY24 and dermatology and nephrology units in ...

Eris Lifesciences on Friday said its consolidated profit after tax declined by 4.5 per cent year on year to Rs 89 crore for the quarter end...

Vedanta's plan to demerge its businesses into separate entities could face hurdles from its minority shareholders and creditors, according ...

Eris Lifesciences on Tuesday said it has acquired a 51 per cent stake in Swiss Parenterals for Rs 637.5 crore. Ahmedabad-based Swiss Parent...

Eris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations b...

The transaction will be financed through borrowings and will achieve financial closure in the next few days, the drug firm said. In a separ...

The nine brands have sales of Rs 87.30 crores for FY22, which represents valuation of 3.9x of the sales of these brands in FY22. The acquir...

The deal for the portfolio that has an annual revenue base of 850 million rupees, will be financed through borrowings, and the transaction ...

The deal, through Eris' dermatology focused unit, is for the purchase of nine brands, including Onabet, Halobate, Sorvate, and Demelan for ...

Through acquisition of Strides domestic formulations portfolio in 2017, Eris Lifesciences got a toehold in the neurology and psychiatry seg...

The launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its reve...

Mumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal...

The brokerage has raised FY21 and FY22 estimated EPS by 2.5% and 3% respectively.

Accumulate Eris Lifesciences Ltd. at a price target of Rs 704.

The India branded generics business being divested by Strides had sales of Rs 181 core FY 2017, the statement said.

The acquisition is Eris’s fourth and the largest buyout in the last 18 months. With this, the company will be among the top ten companies i...

Boards of both the companies are expected to meet on Saturday and a formal announcement is due as early as on Monday, people with knowledge...